Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New research evaluates the efficiency of first-line medication for treating pediatric anxiety disorders

Staff Writer
Staff Writer 3 years ago
Updated 2021/10/23 at 2:24 PM
Share
SHARE

Researchers at the University of Cincinnati conducted a thorough evaluation of the first-line drug treatments used for pediatric anxiety disorders. Based on their findings, published in the Journal of Clinical Psychiatry, they established its efficiency in improving symptoms.

In the study, the research team examined the common use of the selective serotonin reuptake inhibitor (SSRI) known as escitalopram.

SSRIs, which hypothetically increase the neurotransmitter serotonin by inhibiting its reuptake from the synaptic cleft, are the first-line drug choice for the treatment of anxiety disorders in both adolescents and adults.

The examination of escitalopram was initiated using 51 participants aged 12-17. The participants were given either a dose of escitalopram or a placebo for a span of eight weeks. SSRIs generally take several weeks until it reaches its potential full therapeutic effect.

The participants underwent blood tests and other assessments to identify any adversities or concerns during the course of their treatment.

As countless studies have previously indicated, the new UC-based findings also showed that escitalopram was more efficient than a placebo for the alleviation of anxiety in adolescents. In some patients, their symptoms improved faster than others, particularly among slower metabolizers of the SSRI.

“Also, differences in how adolescents break down the medication affected blood levels, and these blood levels predicted certain side effects, like restlessness, jitteriness and insomnia,” researchers stated in a news release.

“For clinicians treating anxious adolescents, this study provides preliminary answers to important questions about the effectiveness of this treatment. It may also help clinicians predict how quickly patients respond and identify which patients may be less likely to get better.”

Photo: Getty Images/Science Photo Library

You Might Also Like

Study boasts MDMA-assisted therapy for PTSD patients

How the brain is organized is revealed by the largest genetic study of brain structure to date

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

New study reveals positive results from postpartum depression treatment Zuranolone

New study explores magic mushrooms for anorexia nervosa psychopathology

TAGGED: anxiety disorders, pediatrics, SSRIs
Staff Writer September 10, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Physical exercise considerably enhances learning and memory in young adults
Next Article New gene discovery may reduce the likelihood of developing alcohol-related cirrhosis

Recommended

Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
Clinical

How the brain is organized is revealed by the largest genetic study of brain structure to date

2 Min Read
Clinical

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

3 Min Read
Clinical

New study reveals positive results from postpartum depression treatment Zuranolone

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?